Join

Compare · MO vs VLON

MO vs VLON

Side-by-side comparison of Altria Group Inc. (MO) and Vallon Pharmaceuticals Inc. (VLON): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MO and VLON operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • MO is the larger of the two at $92.73B, about 3058.7x VLON ($30.3M).
  • MO has hit the wire 1 time in the past 4 weeks while VLON has been quiet.
  • MO has more recent analyst coverage (19 ratings vs 1 for VLON).
MetricMOVLON
Company
Altria Group Inc.
Vallon Pharmaceuticals Inc.
Price
$66.89-0.41%
$12.00+2453.19%
Market cap
$92.73B
$30.3M
1M return
+4.85%
-
1Y return
+14.95%
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
1
0
Recent ratings
19
1
MO

Altria Group Inc.

Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

VLON

Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Latest MO

Latest VLON